Literature DB >> 20077725

[Comparison of antibody persistence between live attenuated and inactivated hepatitis A vaccines].

Huai-Feng Liu1, Xin-Jiang Zhang, Jian-Li Zhang.   

Abstract

OBJECTIVE: To study the antibody persistence of live attenuated hepatitits A vaccine, and to compare the antibody between with inactivated vaccine.
METHODS: 211 HAV susceptible children were divided randomly into three groups, Group A was injected three doses HepA-L at 0, 6 and 12 monthes; Group B was administrated two dose HepA-L at 0 and 6 months, and group C was immunized with inactivated vaccine at month 0 and 6. Serum samples were detected for Anti-HAV at 1, 6, 7, 12, 13, 24, 84 months after vaccination in each group.
RESULTS: The seroconversion rates reached 100% after 2nd dose in all groups. The highest GMC was 2938.1 mlU/ml, founded in group C, and it was 1315.6 mlU/ml and 1586 mlU/ml in group A and B respectively. After the 3rd dose at month 12 in group A, the antibody increased dramatic, which reached 1945.3 mlU/ml. 84 months after first dose in each group, the antibody can be detected from all subjects. Though the GMC in group A declined to 336.8 mlU/ml, it was significant higher than that in group B and C.
CONCLUSION: The good booster effect with HepA-L was well observed in a short-term. The immune response induced by 2 to 3 doses HepA-L could compete with inactivated hepatitis A vaccine. However, long-term effects of both vaccines need further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20077725

Source DB:  PubMed          Journal:  Zhongguo Yi Miao He Mian Yi        ISSN: 1006-916X


  2 in total

Review 1.  Development, production, and postmarketing surveillance of hepatitis A vaccines in China.

Authors:  Fuqiang Cui; Xiaofeng Liang; Fuzhen Wang; Hui Zheng; Yvan J Hutin; Weizhong Yang
Journal:  J Epidemiol       Date:  2014-03-29       Impact factor: 3.211

Review 2.  A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children.

Authors:  Sameer Rao; J S Mao; Salman Motlekar; Zhuang Fangcheng; Ganesh Kadhe
Journal:  Hum Vaccin Immunother       Date:  2016-12       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.